Biotech Values

[genisi]

If the date for that clinical trial slipped, Merck didn't update on that since its 2008 form 10-k, as filed with the SEC on February 27, 2009, where it states:

(“HPS2-THRIVE”) cardiovascular outcomes study, which is expected to be completed in January 2012. Merck anticipates filing an NDA with the FDA for MK-0524A in 2012.